Re: ZEN-3694 Single Agent Trial Status

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: ZEN-3694 Single Agent Trial Status

in response to

Re: ZEN-3694 Single Agent Trial Status

Hartland

posted on Sep 17, 2017 09:28PM

I believe the last we heard from Zenith was BIO International June 20, 2017. However, they only posted slides that contained very little new info. The last webcast was 9 months ago.

3 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply